NCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
Clinical Trials
5 trialsNCT03291886 2022-06-21
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00866333 2019-10-22
ENGAGE-501
Syndax Pharmaceuticals
Phase 2 Terminated
NCT00185302 2015-12-14
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Bayer
Phase 2 Completed
NCT02115594 2014-10-08
ENCORE305
Syndax Pharmaceuticals
Phase 2 Withdrawn